The Hidden Costs of a Prescription for Growth

The world of healthcare investing is a complex landscape comprising pharmaceuticals, biotechnology, and medical equipment companies. Two exchange-traded funds (ETFs) have emerged as prominent players: the VanEck Pharmaceutical ETF (PPH) and the State Street Health Care Select Sector SPDR ETF (XLV). While both offer exposure to global healthcare companies, a closer examination of their cost structures, historical returns, and underlying portfolio concentrations reveals significant differences that may surprise even experienced investors.

The Allure of Diversification

The State Street Health Care Select Sector SPDR ETF’s broad diversification is one of its primary attractions. With 60 positions across medical equipment, healthcare providers, biotechnology, and pharmaceuticals, XLV offers a comprehensive view of the healthcare sector. Its largest holdings include Eli Lilly & Co, Johnson & Johnson, and AbbVie, which together account for nearly 35% of the fund’s portfolio. Launched in 1998, XLV has paid $2.53 per share over the trailing 12 months, yielding 1.6%.

In contrast, the VanEck Pharmaceutical ETF takes a more concentrated approach, tracking the MVIS U.S. Listed Pharmaceutical 25 Index with a tight portfolio of 25 holdings focused exclusively on pharmaceutical research, production, and sales. Top holdings include Eli Lilly & Co, Novartis, and Merck & Co, which together account for over 40% of PPH’s portfolio. Launched in 2011, PPH has paid $2.17 per share over the trailing 12 months, yielding 2.0%.

The Trade-Offs

While XLV offers broad diversification, its expense ratio is significantly higher than that of PPH. This difference may be a persistent cost advantage for the larger, more diversified health sector fund.

However, this comes at the cost of performance. Over the 10-year time frame, XLV has returned 10.1% annualized returns, compared to 8.5% for PPH. In other time-frames, PPH excels, with returns of 13.8% and 10.5% annualized over the 3-year and 5-year look-backs, respectively.

What This Means for Investors

For investors seeking exposure to healthcare companies, the choice between XLV and PPH comes down to performance. While both funds have shown admirable returns, PPH’s superior performance over the past few years makes it a more attractive option. However, this decision should be made with consideration of individual financial goals, risk tolerance, and income requirements.

Investors must also remain vigilant in the complex and rapidly evolving ETF investing landscape. The State Street Health Care Select Sector SPDR ETF’s broad diversification may offer a safety net in uncertain market conditions, but its higher expense ratio may ultimately erode returns.

Performance and Risk

As we move forward into the next quarter, investors would do well to remember that even the best-performing funds can stumble. The VanEck Pharmaceutical ETF and the State Street Health Care Select Sector SPDR ETF are no exceptions. Performance is not a guarantee of future success, and investors must remain adaptable in an ever-changing market.

Ultimately, while both XLV and PPH offer exposure to global healthcare companies, their differences in cost structures, historical returns, and underlying portfolio concentrations reveal significant trade-offs that may surprise even experienced investors. As we navigate the complex world of healthcare investing, it is essential to carefully evaluate performance and make informed decisions about which fund best suits individual financial goals and risk tolerance.